Connect with us


Industrial Lighting Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024


The Industrial Lighting market will register an incremental spend of about $1 billion, growing at a CAGR of 2.13% during the five-year forecast period. A targeted strategic approach to Industrial Lighting sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic. Request free sample pages

Key benefits to buy this report:

  • What are the market dynamics?
  • What are the key market trends?
  • What are the category growth drivers?
  • What are the constraints on category growth?
  • Who are the suppliers in this market?
  • What are the demand-supply shifts?
  • What are the major category requirements?
  • What are the procurement best practices in this market?

Information on Latest Trends and Supply Chain Market Information Knowledge centre on COVID-19 impact assessment

SpendEdge’s reports now include an in-depth complimentary analysis of the COVID-19 impact on procurement and the latest market data to help your company overcome sourcing challenges. Our Industrial Lighting market procurement intelligence report offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.

Insights into buyer strategies and tactical negotiation levers:

Several strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for Industrial Lighting market. The report also aids buyers with relevant Industrial Lighting pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfill their category objectives.

For more insights on buyer strategies and tactical negotiation levers Click Here

To access the definite purchasing guide on the Industrial Lighting that answers all your key questions on price trends and analysis:

  • Am I paying/getting the right prices? Is my Industrial Lighting TCO (total cost of ownership) favorable?
  • How is the price forecast expected to change? What is driving the current and future price changes?
  • Which pricing models offer the most rewarding opportunities?

To get instant access to over 1000 market-ready procurement intelligence reports without any additional costs or commitment, Subscribe Now for Free.

Some of the top Industrial Lighting suppliers listed in this report:

This Industrial Lighting procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.

  • Koninklijke Philips N.V.
  • OSRAM Licht AG
  • Cree Inc.
  • General Electric Co.
  • Eaton Corp. Plc
  • Emerson Electric Co.
  • Hubbell Incorp.
  • Zumtobel Group AG
  • Acuity Brands Lighting, Inc.
  • LG Innotek

This procurement report helps buyers identify and shortlist the most suitable suppliers for their Industrial Lighting requirements by answering the following questions:

  • Am I engaging with the right suppliers?
  • Which KPIs should I use to evaluate my incumbent suppliers?
  • Which supplier selection criteria are relevant for?
  • What are the Industrial Lighting category essentials in terms of SLAs and RFx?

Get access to regular sourcing and procurement insights to our digital procurement platformContact Us.

Table of Content

  • Executive Summary
  • Market Insights
  • Category Pricing Insights
  • Cost-saving Opportunities
  • Best Practices
  • Category Ecosystem
  • Category Management Strategy
  • Category Management Enablers
  • Suppliers Selection
  • Suppliers under Coverage
  • US Market Insights
  • Category scope


About SpendEdge:

SpendEdge shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions. To know more


Anirban Choudhury

Marketing Manager

US: +1 630 984 7340

UK: +44 148 459 9299


IT Tech Packaging, Inc. Advances Additional Orders Negotiation with One of Its Top 5 Customers


BAODING, China, Sept. 24, 2020 /PRNewswire/ — IT Tech Packaging, Inc. (NYSE American: ITP) ("IT Tech Packaging" or "the Company"), a leading manufacturer and distributor of diversified paper products in North China, today announced that the Company is advancing negotiation with one of its top 5 customers, based in Shandong Province for orders of the paper products. The customer is currently ranked among the top 5 customers of the Company during the past couple of years.

Based on the negotiation, the Company and the customer will further cooperate on products supply and purchase in the next quarters and definitive new contracts are expected to be signed by the end of the year. Based on its increasing clients’ demand, the customer will continue to increase its purchase orders from the Company.

Mr. Zhenyong Liu, Chairman and Chief Executive Officer of IT Tech Packaging commented, "We are pleased with the negotiation with the customer for further partnership. As Chinese economy recovers from the COVID-19 epidemic with an amazing pace, our top clients such as companies focusing on printing and packaging are also receiving amount of orders and some even have backlog of orders, so they push forward the negotiations for raw materials and increase purchase volume of our products. We appreciate their confidence in our products as well as efficiency of delivery. We hope the stable partnership between us will continue contributing considerable revenue stream in the upcoming quarters."

About IT Tech Packaging, Inc.

Founded in 1996, IT Tech Packaging, Inc. is a leading manufacturer and distributor of diversified paper products in North China. Using recycled paper as its primary raw material (with the exception of its tissue paper products), ITP produces and distributes three categories of paper products: corrugating medium paper, offset printing paper and tissue paper products. With production based in Baoding and Xingtai in North China’s Hebei Province, ITP is located strategically close to the Beijing and Tianjin region, home to a growing base of industrial and manufacturing activities and one of the largest markets for paper products consumption in the country. ITP has been listed on the NYSE American since December 2009.

Safe Harbor Statements

This press release may contain forward-looking statements. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange Commission, including the Company’s latest annual report on Form 10-K. All information provided in this press release speaks as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to update or revise its forward-looking statements.

For more information, please contact:

At the Company Email:
[email protected]
Tel: +86 0312 8698215

Investor Relations:
Janice Wang
EverGreen Consulting Inc.
Email: [email protected]

Related Links :

Continue Reading


Canadian Municipalities Join Forces With Operation Lifesaver to Raise Awareness About Rail-Crossing Safety


Every year, dozens of Canadians are killed or seriously injured in collisions at railway crossings. In fact, there were 174 such incidents in Canada in 2019, which killed 28 people and seriously injured another 29. Sadly, virtually all these tragedies are preventable.

Today, as part of Rail Safety Week (September 21-27, 2020), Operation Lifesaver Canada is pleased to announce that 125 rail-safety decals are being unveiled in 30 communities across the country as part of OLs Look. Listen. Live. Community Safety Partnership Program.

Through the program, OL works with municipalities to identify locations where bright yellow and black rail-safety decals can be installed near railway crossings. Each decal features a black silhouette of a train, as well as the words Look. Listen. Live.OLs important rail-safety message. The goal of the decals is simple: to prevent tragic crossing incidents by making pedestrians, cyclists and drivers more aware of the need to be extra vigilant around railway crossings.

Incidents at railway crossings are tragically common across this country, and each one affects the victims family and friends, as well as railway employees, first responders and broader communities, said Sarah Mayes, National Director of Operation Lifesaver Canada. “This program aims to make the public more aware of the hazards around rail crossings, which will hopefully save lives. We want people to slow down, look in both directions, listen for approaching trains, and obey all railway warning signs and signals.

Vancouver, B.C., and London, Ont., became the first Canadian cities to sign onto the Community Safety Partnership Program in 2018, and were swiftly followed by seven more municipalities in 2019. OL is delighted that more than two dozen additional municipalities • from Chilliwack to Fredericton Junction and Saskatoon to Kingston • have now joined the program by installing decals in their communities.

Rail safety is a shared responsibility, and were pleased that so many communities have recognized that and chosen to join forces with us through the Community Safety Partnership Program, said Mayes. We hope to build on the programs momentum, and work with even more municipalities to spread the rail-safety message and save lives.

Municipalities can obtain more information about the Community Safety Partnership Program by visiting OLs website. OL also recently unveiled a free toolkit for communities to use in promoting rail safety to their residents; its available at

About Operation Lifesaver Canada

Operation Lifesaver Canada is a national public rail-safety program sponsored by Transport Canada, the Railway Association of Canada and its members, including CN, CP, VIA Rail, Metrolinx, exo, West Coast Express and Genesee & Wyoming, among others. Through its national network of Rail Safety Ambassadors, partnerships with safety councils, police, the trucking industry and community groups, and innovative tools such as its virtual-reality Look. Listen. Live. campaign, Operation Lifesaver Canada works to save lives by educating Canadians about the hazards of rail crossings and trespassing on railway property. Canadians can keep up-to-date on the latest rail safety news by visiting

Maryse Bétournay

Operation Lifesaver Canada

[email protected]


Continue Reading


Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist


Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist that is being developed for the treatment of VMS, commonly known as hot flashes and night sweats, in menopausal women.

We are pleased to advance MLE-301 into clinical development, prioritizing our resources on this valuable asset and leveraging Millendos expertise in the NK3R category,” said Julia C. Owens, President and Chief Executive Officer of Millendo Therapeutics. The company is focused on executing our Phase 1 study and understanding more about the safety, PK/PD and efficacy profile of MLE-301 based on the resulting data from this study.”

The first-in-human trial is designed to evaluate the safety and tolerability of MLE-301. The single ascending dose portion of the study will be conducted in healthy male volunteers, to determine the pharmacokinetics of MLE-301 and its pharmacodynamic profile as measured by reductions of biomarkers (luteinizing hormone, testosterone). The Phase 1 multiple ascending dose portion will enroll post-menopausal women, allowing measurement of reductions in VMS frequency and severity, and establishment of initial clinical proof of concept. The Phase 1 clinical trial is supported by strong preclinical data that showed potency and selectivity for the NK3R receptor, the potential for once-daily dosing, and testosterone lowering effects consistent with the expected activity of an NK3R antagonist. Based on its demonstrated in vitro and in vivo activity, Millendo believes MLE-301 may have meaningful clinical impact in an area of high unmet medical need.

“Over 20 million women in the U.S. suffer from VMS associated with menopause, including hot flashes and night sweats that can severely impact quality of life, overall productivity and long-term healthcare utilization,” said Christophe Arbet-Engels, M.D., Ph.D., Chief Medical Officer of Millendo Therapeutics. With symptoms that last on average over seven years, there is still a critical need for an effective, non-hormonal treatment that has the efficacy of estrogens but without the increased risks of cancer or cardiovascular disease.”

About MLE-301

MLE-301 is a neurokinin 3 receptor (NK3R) antagonist that is being developed as a potential treatment of vasomotor symptoms (VMS), commonly known as hot flashes and night sweats, in menopausal women. NK3R plays a key role in regulating the activity of KNDy (kisspeptin/NKB/dynorphin) neurons, which has been shown to participate in the generation of VMS. By inhibiting the NK3R signaling on the KNDy neurons and potentially other NK3R-expressing neurons that propagate heat dissipation signals through the hypothalamus, MLE-301 aims to reduce the effects of hyperactive KNDy neurons and thereby decrease the frequency and severity of vasomotor symptoms.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the words may, might, will, could, would, should, expect, intend, plan, objective, anticipate, believe, estimate, predict, project, potential, continue and ongoing, or the negative of these terms, or other comparable terminology intended to identify statements about the future. These include statements with respect to the Phase 1 clinical trials for and the potential clinical impact of MLE-301 on menopausal vasomotor symptoms, and, therefore, you are cautioned not to place undue reliance on them. Such forward-looking statements are based on Millendos expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including that Millendo has incurred significant losses since inception, Millendo has a limited operating history and has never generated any revenue from product sales, Millendo will require additional capital to finance its operations, Millendo’s future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Millendo’s clinical trials may not support Millendo’s product candidate claims, Millendo may encounter substantial delays in its clinical trials or Millendo may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Millendo’s control, Millendo’s product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Millendo faces substantial competition and Millendos business, preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by the current COVID-19 pandemic. You should refer to the risk factor disclosure set forth in the periodic reports and other documents Millendo files with the Securities and Exchange Commission available at, including without limitation Millendos Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020.

New factors emerge from time to time and it is not possible for Millendo to predict all such factors, nor can Millendo assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to Millendo as of the date of this press release. Millendo disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

Millendo Investor Contact:

Connie Chang

Millendo Therapeutics


[email protected]

Millendo Media Contact:

Julie Bane



[email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News24 mins ago

IT Tech Packaging, Inc. Advances Additional Orders Negotiation with One of Its Top 5 Customers

BAODING, China, Sept. 24, 2020 /PRNewswire/ — IT Tech Packaging, Inc. (NYSE American: ITP) ("IT Tech Packaging" or "the Company"),...

gbafNews28 gbafNews28
News2 hours ago

Glucuronolactone Market Procurement Intelligence Report With COVID-19 Impact Analysis | Global Forecasts, 2020-2024 | SpendEdge

The Glucuronolactone market will register an incremental spend of about $86 million, growing at a CAGR of 4.53% during the...

gbafNews28 gbafNews28
News2 hours ago

Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research

DexCom, Inc. (NASDAQ:DXCM) today announced it has signed a five-year collaboration agreement with the University of Virginia to advance its...

gbafNews28 gbafNews28
News2 hours ago

Solomon D. Trujillo Appointed to Chairman of Encantos

Encantos, the award-winning entertainment-driven edtech company creating direct-to-learner family brands, announced today that Solomon (Sol) Trujillo has been appointed as...

gbafNews28 gbafNews28
News2 hours ago

Phunware Announces Upward Revision to Third Quarter Net Revenues Guidance

Phunware, Inc. (NASDAQ: PHUN) (the Company), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services...

gbafNews28 gbafNews28
News2 hours ago

Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant...

gbafNews28 gbafNews28
News2 hours ago

Canadian Municipalities Join Forces With Operation Lifesaver to Raise Awareness About Rail-Crossing Safety

Every year, dozens of Canadians are killed or seriously injured in collisions at railway crossings. In fact, there were 174...

gbafNews28 gbafNews28
News2 hours ago

Jitsi and Mattermost Team Up for Joint Hackathon – “Thriving in a Remote Environment”

8×8, Inc. (NYSE: EGHT), a leading integrated cloud communications platform, today announced a joint hackathon hosted by Jitsi and Mattermost...

gbafNews28 gbafNews28
News2 hours ago

OSI Systems Receives $59 Million Contract to Provide Security Inspection Systems to Hamad International Airport

OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced that its Security division was awarded a contract...

gbafNews28 gbafNews28
News2 hours ago

IDC Launches the Future of Industry Ecosystems: Built on the Platform and Sharing Economy

The tactical and strategic priority list for leadership, built on the premise of a steady rate of change, has changed...